Relevium Reports Revenue Growth in the First 50 Days of Business and Guidance Update
Relevium Reports Revenue Growth in the First 50 Days of Business and Guidance Update
Momentum Public Relations
Press Release: August 2, 2017
MONTREAL, QUEBEC–(Marketwired – Aug. 2, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) a publicly traded corporation strategically focused on the acquisition of e-retail brands, products and technologies in the health and wellness market is pleased to provide guidance on its strategy and focus for the balance of calendar year 2017.
Highlights
- Successful first 50 days of operations
- Since closing BioGanix acquisition: revenues of approx. C$ 700,000 (~53{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} increase over previous period last year)
- Guidance on expansion of BioGanix
- Guidance for M&A
- Guidance for technology builds
Successful first 50 days of operations
On June 6, 2017, Relevium acquired the assets and business of BioGanix, the Company’s first acquisition of e-retail assets. Management and the previous owner of BioGanix have been working diligently to ensure a smooth transition of the business. Jointly, careful detailed transitioning of the online operations has been ongoing in order to avoid any possible disruptions to the daily business operations.
The Company is happy to announce that the initial transition of the current business has been successful, and Relevium has recorded revenues of approximately CAD$700,000 since closing, representing a 52{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} increase over the previous period last year (47{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} increase taking into account the effect of FX fluctuations).
In the month of August, management will be working closely with the previous ownership to optimize operations and making additions to the current product offering.
Aurelio Useche, CEO, stated: “We are extremely pleased with the dedication and professionalism demonstrated by the previous ownership, the staff and our internal team during this initial phase of work.” Mr. Useche continued: “We look forward to this continued partnership as we move into the optimization phase of the transition.”
Guidance on Expansion of BioGanix
As part of the overall acquisition strategy, Relevium will spend considerable time in optimizing and developing the acquired e-retail business and brands starting with BioGanix. The Company’s model includes:
- Optimization of its marketing and product positioning strategies
- Overview of its current product line and launching of new products
- Creation and launch new brands and product segments
- Obtaining licenses or direct sourcing of exclusive products
- Joint Ventures for market expansions
Management is in discussions with potential partners in the above areas, including Hempco. As previously announced on May 10, 2017, the Company is currently working with Hempco to launch a vegan nutrition and vegan nutraceutical line to be launched in fall 2017 pending marketing studies and analysis.
Pierre Bertrand, Director and Member of the Strategy Committee, stated: “The board, in conjunction with the CEO, have established a clear plan for creating value through the newly acquired business of BioGanix.” Pierre Bertrand further stated: “We strongly believe that success in acquisitions is measured through acceleration of the inline business, based on excellence in execution of the underlying businesses acquired. As such, Relevium is committed to the success of the BioGanix business.”
Guidance on Future Acquisitions and Current Pipeline
In alignment with its overall business strategy, Relevium continues to build its pipeline of potential M&A targets. Although the list of targets is dynamic, the Company’s current pipeline represents a potential list of eight targets of interest totalling over $80M in Revenues and $24M in EBIT (all figures in Canadian Dollars).
Depending on several factors such as market conditions and ability to finance, the Company intends to execute on at least one other transaction by the end of 2017.
Guidance on Technology Development
Relevium Technologies is headquartered in Montreal, Quebec, a leading center for innovation in Big Data, Artificial Intelligence and Machine Learning. In addition to optimizing operations, marketing spend and brand equity, Management believes that an investment in Big Data and Artificial Intelligence will be of strategic importance in creating value for the Company and its shareholders.
Relevium has already entered into discussions with leading Montreal-based companies in this sector in order to evaluate and set the direction for the development of proprietary technologies. The envisioned technology builds will allow for data driven decision making for operations, product launches, brand building and marketing as well as any other facet of the business that may come to light during the process. The envisioned technology builds will benefit from continuous learning as datasets grow and the technology evolves.
The Company recognizes that certain key tools required to be a leader in the e-commerce industry are not commercially available. As such the Company will build artificial intelligence and machine learning solutions so as to ensure that it is at the bleeding edge of the industry and that portfolio brands outperform the market peer group.
Aurelio Useche, CEO of Relevium Technologies stated: “Success in e-commerce was traditionally linked to marketing spend and operations optimization. We believe that the current and future success of e-retail will not only depend on these two pillars, but also in understanding market trends and consumer behaviour data, an area of critical investment by Relevium.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Renmark Financial Communications Inc.
Steve Hosein
(416) 644-2020 or (514) 939-3989
shosein@renmarkfinancial.com
www.renmarkfinancial.com
Relevium Technologies Inc.
investors@releviumtechnologies.com
www.releviumtechnologies.com
https://www.facebook.com/releviumcorp/
Tweets by RELEVIUMCORP
https://www.linkedin.com/company-beta/10345441/
- Published in Life Sciences, News Home, Relevium Technologies, Technology
Relevium Technologies (RLV:tsxv) Provides Corporate Update
Relevium Technologies (RLV:tsxv) Provides Corporate Update
– Momentum Public Relations –
Press Release: Sept. 27, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to provide the following corporate update on its ongoing activities.
UPDATE ON PRIVATE PLACEMENT
As announced on August 19, 2016, the Company closed a private placement and issued an aggregate of 5,058,000 units of the Company (the “Units”), at a price of $0.10 per Unit, for gross proceeds of $505,800 to the Company (the “Private Placement”). As previously announced, on July 6, 2016, a portion of the private placement representing 1,500,000 Units required the approval by the shareholders of Maestro Capital Corporation (the subscriber). The Company is pleased to confirm that the shareholders of Maestro approved the investment as at August 31, 2016. The TSX Venture Exchange is currently holding the subscription funds from Maestro and the corresponding units in trust pending receipt of final approval.
UPDATE ON BUSINESS ACTIVITIES
The Company is pleased to inform shareholders that it continues to pursue acquisition targets in the lucrative and largely fragmented wellness and wellness e-commerce industries. Management is currently engaged in discussions with several strategic acquisition targets in the spaces.
In the case of the most advanced target, the Company has retained the accounting firm Ernst & Young LLP in Montreal to start a financial and structuring due diligence process. At the current time there is no binding agreement between the Company and the aforementioned target.
The Company believes that pursuing a disciplined acquisition strategy is the best way to grow its business and create long-term value for shareholders.
Andre Godin, Chairman and Leena Lakdawala, CEO explained: “We want to make sure our shareholders develop a clear picture of the Company’s bricks and clicks strategy and overall direction. For this reason Relevium will be structured to operate two separate business units: Relevium Wellness, which will operate a network of innovative wellness clinics and Relevium E-tail, which will operate successful and profitable E-Commerce platforms.”
UPDATE ON LETTER OF INTENT
Pursuant to an announcement made on May 19, 2016 that stated that the Company had executed a letter of intent (the “LOI”) to acquire a controlling interest and progressively 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of a Montreal-based B2B distribution and D2C E-retail company. The Company announced today that due to lack of strategic fit, the parties are no longer pursuing the transaction and have mutually decided to terminate the LOI.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
- Published in Bio technology, News Home, Relevium Technologies, Technology
Relevium Technologies (RLV.V) Announces Closing of Private Placement
Relevium Technologies (RLV.V) Announces Closing of Private Placement
– Momentum Public Relations –
Press Release: August 19, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to announce that it has completed closing of its previously announced private placement.
The Company has issued an aggregate amount of 5,058,000 units of the Company (the “Units”) at a price of $0.10 per Unit, for gross proceeds of $505,800 to the Company (the “Private Placement”). Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant entitling the holder thereof to purchase one Common Share at a price of $0.15 until August 19, 2019. Each Unit will be subject to a statutory hold period of four months and one day from the date of closing.
The Company will use the proceeds from the Private Placement for general corporate purposes.
The Private Placement is subject to the final approval of the TSX Venture Exchange (“TSXV”) as well as other customary closing conditions. Pursuant to an announcement made on July 6, 2016, a portion of the private placement representing 1,500,000 units is further subject to the approval by the shareholders of Maestro Capital Corporation (the subscriber) and the funds will be held in trust until such approval takes place on or before August 31, 2016.
In connection with the Private Placement, the Company paid finder fees in the amount of $2,000 in cash plus 20,000 in Broker Warrants.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities of 1933, as amended, or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
- Published in Bio technology, News Home, Relevium Technologies, Technology
Relevium (RLV:tsxv) Announces Partnership Agreement With Hong Kong Based Technology Product Developer
Relevium Announces Partnership Agreement With Hong Kong Based Technology Product Developer
– Momentum Public Relations –
Press Release: July 13, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV) (FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to announce it has executed a cooperation agreement with Radcon Consulting, a leading “Connected” and “Wearable” technology product designer based in Hong Kong and with offices in China.
Pursuant to the terms of the cooperation agreement, Radcon Consulting will provide Technical Evaluation, Design, Engineering, Project Management and Go-to-Market services in addition to providing investment opportunities in leading edge wearable and connected devices and/or technologies in the areas of Health, Wellness and Sports Performance.
Leena Lakdawala, CEO of Relevium stated: “According to the Consumer Electronics Association®, the connected Personal Health and Wellness market is expected to reach 8 billion by 2018 and Relevium is planning to access this market through unique and innovative products and/or technologies at the peak of the innovation cycle”. She added further “The partnership with Radcon Consulting ensures continued technology flow that will drive the innovation engine behind our consolidation of e-retail asset strategy”
Conrad Lee, CEO of Radcon Consulting stated: “We are excited and delighted to be a partner of Relevium. This cooperation truly strengthens and expands the reach and services for both companies to many innovative and disruptive technologies and investment opportunities”
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
About Radcon Consulting.
Radcon Consulting is a privately held company focused on providing a full suite of services equipped to take concepts from basic design to reality, handling all the technical details while its customers focus on innovation. The company provides Project Management, Electronic/mechanical Design, Software & Firmware Design, Engineering & Manufacturing, Intellectual Property Management, and Go-to-Market as well as other comprehensive services.
- Published in Bio technology, News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Announces Private Placement by Maestro Capital
Relevium Announces Private Placement by Maestro Capital
– Momentum Public Relations –
Press Release: July 6, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) in conjunction with Maestro Capital Inc. (TSX.P – “MCP”) is pleased to announce that the two parties have agreed to the terms of participation by Maestro in a non-brokered private placement offering (the “Private Placement”).
Pursuant to the agreed terms, Maestro will subscribe by way of subscription agreement for a minimum of 1,500,000 units (the “Units”) of Relevium at a per Unit price of $0.10 for gross proceeds of $150,000. Each unit will consist of one common share in the capital of Relevium (a “Relevium Share”) and one common share purchase warrant, each whole warrant (a “Warrant”) will entitle Maestro to purchase one common share in the capital of Relevium at a per share price of $0.15 for a period of 36 months from the date of closing of the Private Placement.
Completion of the proposed Transaction is subject to a number of conditions, including but not limited to, execution by the parties of a form of subscription agreement for the Private Placement, the receipt of all requisite corporate and regulatory approvals, shareholder and TSX approval. The Exchange’s acceptance of the Transaction will be conditional, among other things, on Maestro filing with the Exchange all documents in compliance with Exchange CPC Policy requirements. The proposed Transaction cannot close until the required approvals are obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Relevium also announced its intention to extend the private placement for a minimum of 5,000,000 Units and a maximum of 10,000,000 under the same terms, which may close in one or more tranches, for total gross proceeds of between $500,000 and $1,000,000. All securities issued by Relevium in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance of the securities in accordance with applicable securities legislation.
Leena Lakdawala, CEO of Relevium stated: “Management is very pleased with the vote of confidence received today from Maestro Capital and its constituents. We have every intention to follow through on our current initiatives and we look forward to welcoming all of Maestro’s shareholders into Relevium”
Relevium also announced its intention to extend the expiry date of the 10,015,466 share purchase warrants issued pursuant to the August 2015 private placement closed concurrently with the completion of its Qualifying Transaction as Ovid Capital. The expiry term of the share purchase warrants will be extended for an additional term of two years and will now expiry on August 18, 2018. The extension of the warrants is subject to the regulatory approval by the TSX.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
“Leena Lakdawala“
CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Technologies Signs LOI to Acquire a Controlling Interest in a Montreal-Based Distribution Company
Relevium Technologies Signs LOI to Acquire a Controlling Interest in a Montreal-Based Distributuon Company
– Momentum Public Relations –
Press Release: May 19, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to announce it has executed a letter of intent to acquire a controlling interest and progressively 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of a Montreal-based B2B distribution and D2C E-retail company that specializes on high quality exclusive performance products and technologies for North America.
The acquisition target is a growing distribution and D2C company with an existing revenue base of over $500,000.00 CAD through a narrow and focused number of products, which are expected to grow organically at a rate of 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per year. The acquisition target is currently in the process of negotiating the expansion of its product offering and is anticipating introducing several new SKUs, all of which are expected to translate into significant increase in market reach and revenues. The proposed transaction, the details of which will be disclosed upon execution of a definite agreement, is expected to become Relevium’s main distribution and E-retail capability for new technologies and exclusive products for North America by leveraging its experienced team and established relationships with specialty stores and major retail chains across the US and Canada.
In addition to the current performance products sold by the acquisition target, Relevium also plans to utilize and leverage the new partnership to develop a new platform for launching, distributing and retailing connected sports performance products, specialized nutritional supplements, innovative pain management devices and recovery products, all in line with the Company’s overall strategy. The addition of the new products and technologies as well as the addition of E-retail capabilities are estimated to materially increase revenues and as well as branding strength of the Company.
Leena Lakdawala, CEO of Relevium Technologies stated: “As part of our growth strategy, this partnership is expected to provide Relevium access to an established and growing network of performance and wellness retailers both in Canada and the US. The proposed target counts with an experienced team who truly understands the role of relationship and trust-based selling, both of which represent the basis for a successful distribution, retail and D2C strategy”
The transaction is expected to close within the next 30 days and is subject to customary due diligence, market compliance and financing.
About Relevium Technologies Inc.
Relevium is a TSXV listed company (TSX VENTURE:RLV) focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery andPerformance. Relevium currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
“Leena Lakdawala”
CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies
Relevium Technologies Returns 8,612,500 Shares to Treasury
Relevium Technologies Returns 8,612,500 Shares to Treasury
– Momentum Public Relations –
Press Release: April 22, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to announce it has received approval from the TSX Venture Exchange (the “Exchange”) regarding the cancellation of 8,612,500 previously issued shares relating to the acquisition of the assets of BIOflex Medical Magnetics, Inc. (the “Qualifying Transaction”) leaving the Company with a total of 29,525,966 common shares outstanding.
Leena Lakdawala, CEO of Relevium stated: “Management has been working diligently to create value for our shareholders. We have just returned over 8.5 million shares to the Company’s treasury, reducing the outstanding shares to fewer than 30 million and effectively cutting the cost of the BIOflex acquisition down by 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. Relevium has recently executed an Exclusive Supply Agreement for our patented magnetic technology with Back-A-Line Inc., a California-based leader in back pain solutions, and the Company remains actively engaged in identifying additional assets within the growing global health and wellness market.”
Pursuant to Relevium’s news release dated February 29, 2016, the Company, BIOflex and iTech Medical, Inc. have agreed to adjust the purchase price under the Purchase Agreement (the “Purchase Price Adjustment”). As part of, and in satisfaction of, the Purchase Price Adjustment: (i) BIOflex shall return a total of 8,612,500 common shares in the capital of the Company which it currently owns to the Company for cancellation; (ii) the Company shall issue 1,722,500 common share purchase warrants to BIOflex (which shall be restricted and legended pursuant to applicable Canadian and U.S. securities laws), with each warrant being exercisable to acquire one common share in the capital of the Company, at a price of $0.1125 per share (being the same issue price as the securities transacted pursuant the Qualifying Transaction and representing a premium to the current market price of the Company’s common shares on the TSX Venture Exchange), for a period of three years from the date of issuance of the warrants; and (iii) the Company shall release the right of first refusal in respect of the muscle pattern recognition (MPR) technology of iTech Medical, Inc.
In addition, and as part of the discussions relating to the Purchase Price Adjustment, the Company has determined to settle the $225,000 loan owing from iTech Medical, Inc., as well as any accrued interest thereon. Other than as regards the Purchase Price Adjustment, terms and conditions and the duties and obligations of the parties pursuant to the Purchase Agreement continue in full force and effect.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Leena Lakdawala, CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies
Relevium Technologies Provides Corporate Update
Relevium Technologies Provides Corporate Update
– Momentum Public Relations –
Press Release: April 6, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to provide an update regarding the previously announced corporate roll-up strategy, focused on acquiring products, technologies or companies within the rapidly expanding global health and wellness sector.
In addition to undergoing initiatives to commercialize, partner and license its Patented Technology, Relevium has entered into discussions with potential acquisition targets consisting of revenue generating and profitable businesses well aligned with the Company’s strategy and market focus. Management plans to continue to provide progress updates and anticipates it will enter into exclusive discussions with some of these targets during the second quarter of this calendar year.
In addition to products and technologies for Pain, Recovery and Performance, management is also examining opportunities in the delivery of comprehensive wellness services. Management believes that the growth in the wellness sector of the economy will be fueled by Baby Boomers, which represent approximately one third of the U.S. and Canadian population. This is historically the largest, most active and health conscious consumer group entering pre-retirement. This consumer group seeks a balanced and active lifestyle combined with personalized care and unique product offerings, all as viable alternatives to pharmaceutical prescription drugs.
Leena Lakdawala, CEO of Relevium Technologies Inc. stated: “The global health and wellness market is projected to hit record high levels by 2017, and today’s informed consumers are choosing a balanced lifestyle focused on health and wellness. People are staying active longer and eating healthier to avoid disease and medication dependencies. Relevium’s corporate strategy aims at leveraging this growing demand by strategically defining three unique verticals of Pain Relief, Recovery and Performance and offering unique deliverables under one company.”
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
“Leena Lakdawala“
CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Technologies Enters Into Exclusive Supply Agreement
Relevium Technologies Enters Into Exclusive Supply Agreement
– Momentum Public Relations –
Press Release: April 4, 2016
Relevium Technologies Inc. (TSX VENTURE: RLV) (FRANKFURT: 6BX) is pleased to provide an update on its corporate strategy, which is primarily focused on the acquisition of products or companies within three major verticals in the health and wellness sector: Pain Relief, Recovery and Performance.
Relevium is pleased to announce that it has executed an Exclusive Supply Agreement of its patented magnetic technology with Back-A-Line Inc., a California-based leader in back pain solutions. Relevium will provide its latest patented magnetic field technology for insertion in the company’s Dynamic Back Support system, which combined, will help improve healing and pain management for back related injuries. Back-A-Line sells its Dynamic Back Support across many industries, including air transport, food and grocery, health care, trucking, and manufacturing as well as public sector unions and the US Army.
“We are very excited about this initial cooperation between Relevium and Back-A-Line Inc., and we believe that the combination of their unique patented design and our technology will prove to be a great source of relief to those suffering from back pain” stated Bill Landtbom, CEO of Back-A-Line Inc. He stated further: “This unique combined wearable was devised specifically for chronic back pain, a market of approximately 20M adults in the US alone. In our opinion, no other device and “conservative” protocol can provide the same effective alternative to pharmaceuticals and surgery”.
“We are pleased with this initial partnership and we believe that the passion, dedication and product offering of Back-A-Line is an ideal fit for our technology. The combination of their Dynamic Belt Support product with our patented technology will provide their customers with a unique and effective solution for dealing with back pain and overall wellbeing”, stated Leena Lakdawala, CEO of Relevium Technologies.
The company remains actively engaged in identifying ecommerce assets within its three active verticals and is currently reviewing several candidates that fit well with the Company’s strategy. Additionally, the Company is exploring the opportunity to provide services in this sector.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
“Leena Lakdawala“
CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies, Technology, Uncategorized